Furthermore,since SGLT-1 is highly expressed in the sarcolemma of myocardial cells in humanautopsy hearts and mouse-perfused hearts [134], sotagliflozin may offer moredirect cardiovascular benefits to patients and has the potential to replacedapagliflozin and empagliflozin as the first-line option for clinicians in thetreatment of heart failure. This evidence concerns the gene SLC5A1 and heart failure.